| New Phosphate Binder/Anti-oxidant Therapy |
PiLo™ (Calcium/magnesium/R-alpha-lipoate combination)
- Target Indication: Stage 5 Chronic Kidney Disease, with possible expansion to Stage 3/4 patients
- Worldwide patents under examination
- Therapeutics & Safety
- Early testing shows excellent phosphate binding throughout GI tract
- No acid reflux
- Expected to lower vascular calcification
- Expected to increase quality of life
|
|
PiLo™ is an NDA candidate.
PiLo™ is available for licensing.
|
|
|
